Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons

Clinical and Vaccine Immunology

Volumn 21, Issue 9, 2014, Pages 1339-1342

  Keck, James W ^a,b,d   Bulkow, Lisa R ^b   Raczniak, Gregory A ^a,b   Negus, Susan E ^c   Zanis, Carolyn L ^b   Bruce, Michael G ^b   Spradling, Philip R ^a   Teshale, Eyasu H ^a   McMahon, Brian J ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium ^*  (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPTAVAX; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; HEPATITIS B ANTIBODY;

ADOLESCENT; ADULT; ALASKA NATIVE; ANTIBODY TITER; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; MALE; PRIORITY JOURNAL; VACCINATION; BLOOD; CHILD; IMMUNIZATION; IMMUNOLOGY; INFANT; NEWBORN; POPULATION GROUP; PRESCHOOL CHILD; TIME; UNITED STATES;

ADOLESCENT; ADULT; ALASKA; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; MALE; POPULATION GROUPS; TIME FACTORS;

EID: 84940304302     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00263-14     Document Type: Article

References (13)

1. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, Nostro AL. 2003. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 21: 685-691. http://dx.doi.org/10.1016/S0264-410X(02)00580-7. (Pubitemid 36091979)
2. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, Bulkow LR, Wainwright RB. 2000. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J. Infect. Dis. 181:413-418. http://dx.doi.org/10.1086/315259. (Pubitemid 30131804)
3. Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Bocher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV. 2005. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23:4158-4166. http://dx.doi.org/10. 1016/j.vaccine.2005.03.017. (Pubitemid 40814591)
4. European Consensus Group on Hepatitis Immunity B. 2000. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561-565. http://dx.doi.org/10.1016/S0140-6736(99)07239-6.
5. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. 2009. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 200:1390-1396. http://dx.doi.org/10.1086/606119.
6. But DY-K, Lai C-L, Lim W-L, Fung J, Wong DK-H, Yuen M-F. 2008. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 26: 6587-6591. http://dx.doi.org/10.1016/j.vaccine.2008.09.034.
7. van der Sande MAB, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC. 2007. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One 2:e753. http://dx.doi.org/10.1371/journal.pone.0000753.
8. Banatvala J, Van Damme P, Oehen S. 2000. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19:877-885. http://dx.doi.org/10.1016/S0264-410X(00)00224-3.
9. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, Bell BP. 2007. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 120:e373-e381. http://dx.doi.org/10.1542/peds.2007-0131. (Pubitemid 47219488)
10. Williams JL, Christensen CJ, McMahon BJ, Bulkow LR, Cagle HH, Mayers JS, Zanis CL, Parkinson AJ, Margolis HS. 2001. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 19:4081-4085. http://dx.doi.org/10.1016/S0264-410X(01)00112-8. (Pubitemid 32566334)
11. Bruce MG, Bruden DL, Hurlburt D, Zanis CL, Thompson GC, Rea LD, Toomey M, Townshend-Bulson LJ, Rudolph K, Bulkow LR, Spradling P, Baum R, Hennessy TW, McMahon BJ. 2013. Antibody levels and protection after hepatitis B vaccine: results of a 30 year follow-up study and response to a booster dose, abstr 187, p 300A. 64th Annu. Meet. Am. Assoc. Study Liver Dis. Liver Meet. 2013. http://dx.doi.org/10.1002/hep.26822.
12. Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, de Perio MA, Reilly M, Byrd K, Ward JW; Centers for Disease Control and Prevention (CDC). 2013. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm. Rep. 62(RR-10):1-19.
13. Bauer T, Jilg W. 2006. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24:572-577. http://dx.doi.org/10.1016/j.vaccine.2005.08. 058. (Pubitemid 43017822)